Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 112
Filtrar
3.
Nature ; 2024 May 30.
Artículo en Inglés | MEDLINE | ID: mdl-38816474
5.
Adv Sci (Weinh) ; 11(17): e2309721, 2024 May.
Artículo en Inglés | MEDLINE | ID: mdl-38468355

RESUMEN

High-resolution spatio-temporal monitoring of the cell membrane lipid order provides visual insights into the complex and sophisticated systems that control cellular physiological functions. Solvatochromic fluorescent probes are highly promising noninvasive visualization tools for identifying the ordering of the microenvironment of plasma membrane microdomains. However, conventional probes, although capable of structural analysis, lack the necessary long-term photostability required for live imaging at the cellular level. Here, an ultra-high-light-resistant solvatochromic fluorescence probe, 2-N,N-diethylamino-7-(4-methoxycarbonylphenyl)-9,9-dimethylfluorene (FπCM) is reported, which enables live lipid order imaging of cell division. This probe and its derivatives exhibit sufficient fluorescence wavelengths, brightness, polarity responsiveness, low phototoxicity, and remarkable photostability under physiological conditions compared to conventional solvatochromic probes. Therefore, these probes have the potential to overcome the limitations of fluorescence microscopy, particularly those associated with photobleaching. FπCM probes can serve as valuable tools for elucidating mechanisms of cellular processes at the bio-membrane level.


Asunto(s)
Colorantes Fluorescentes , Microscopía Fluorescente , Colorantes Fluorescentes/química , Humanos , Microscopía Fluorescente/métodos , Imagen Óptica/métodos , Membrana Celular/metabolismo , Membrana Celular/química
11.
Nature ; 621(7979): 646-648, 2023 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-37723291
12.
Nature ; 2023 Sep 20.
Artículo en Inglés | MEDLINE | ID: mdl-37730775
13.
BMC Gastroenterol ; 23(1): 234, 2023 Jul 12.
Artículo en Inglés | MEDLINE | ID: mdl-37438735

RESUMEN

BACKGROUND:  Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide, and is characterized by insidious onset, rapid progression, and poor prognosis. Immunotherapy is a first-line treatment for advanced HCC. The identification of immune-related prognostic markers may be an effective strategy to predict and improve clinical response rate of immunotherapy. METHODS:  The DESeq2, edgeR, and limma R packages were used to compare the transcriptomes of HCC with different prognoses. Cancer-related databases such as UALCAN, TNMplot, GEPIA, muttarget and Human Protein Atlas (HPA), and the Kaplan-Meier Plotter platform were used to analyze the relationship between CLDN18 and the clinical characteristics, as well as prognosis of HCC. The co-expressed genes of CLDN18 were obtained from LinkedOmics platform, and GO functional enrichment and KEGG pathway analysis were performed. The CIBERSORT, TIMER, Timer 2.0 and TISIDB algorithms were used to analyze immune infiltration. RESULTS:  CLDN18 was differentially expressed in HCC patients with different prognoses, and its expression level in PBMC was positively correlated with the stage of BCLC. In addition, CLDN18 was significantly overexpressed in HCC tumor tissues compared to adjacent non-tumor tissues, which was consistent with PBMC sequencing results and immunohistochemical data from human protein profiles. CLDN18 was also positively correlated with HCC staging and grading, and high expression levels of CLDN18 predicted shorter overall survival. Functional annotation of CLDN18 in HCC revealed enrichment of the cellular senescence and protein activation cascade, along with biological processes such as cell cycle, inflammatory response, and cellular ketone metabolism. In addition, CLDN18 was also associated with tumor infiltrating immune cells, suppressive immune cell markers, T lymphocyte depletion and activation of HCC, and low expression of CLDN18 was associated with higher CD8 + T cell infiltration and better survival rates. CONCLUSIONS: CLDN18 is a potential prognostic marker and immunotherapeutic target for HCC.


Asunto(s)
Carcinoma Hepatocelular , Neoplasias Hepáticas , Humanos , Pronóstico , Carcinoma Hepatocelular/genética , Leucocitos Mononucleares , Neoplasias Hepáticas/genética , Algoritmos , Claudinas
14.
Nature ; 2023 Jul 28.
Artículo en Inglés | MEDLINE | ID: mdl-37507506
15.
Nature ; 2023 Jun 08.
Artículo en Inglés | MEDLINE | ID: mdl-37291475
16.
IET Nanobiotechnol ; 17(4): 368-375, 2023 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-37153957

RESUMEN

Ellagic acid (EA), which is widely distributed in many foods, has been found to possess inhibitory activity against xanthine oxidase (XO). However, there is ongoing debate about the difference in XO inhibitory activity between EA and allopurinol. Additionally, the inhibitory kinetics and mechanism of EA on XO are still unclear. Herein, the authors systematically studied the inhibitory effects of EA on XO. The authors' findings showed that EA is a reversible inhibitor with mixed-type inhibition, and its inhibitory activity is weaker than allopurinol. Fluorescence quenching experiments suggested that the generation of EA-XO complex was exothermic and spontaneous. In silico analysis further confirmed that EA entered the XO catalytic centre. Furthermore, the authors verified the anti-hyperuricemia effect of EA in vivo. This study elucidates the inhibition kinetics and mechanism of EA on XO, and lays a theoretical foundation for the further development of drugs and functional foods containing EA for the treatment of hyperuricemia.


Asunto(s)
Alopurinol , Hiperuricemia , Humanos , Alopurinol/farmacología , Alopurinol/uso terapéutico , Inhibidores Enzimáticos/farmacología , Inhibidores Enzimáticos/uso terapéutico , Xantina Oxidasa/metabolismo , Xantina Oxidasa/uso terapéutico , Ácido Elágico/farmacología , Ácido Elágico/uso terapéutico , Cinética , Hiperuricemia/tratamiento farmacológico
18.
Nature ; 2023 May 11.
Artículo en Inglés | MEDLINE | ID: mdl-37173441
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...